10. A method for the treatment or prevention of hematological disorders, in particular for the treatment in sickle cell disease and thalassemia, or for the treatment of the iron overload syndrome, in particular for the treatment of hereditary hemochromatosis in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a GlyT1 inhibitor according to any one of claims 5 to 9.

11. A pharmaceutical composition comprising a GlyT1 inhibitor according to any one of claims 5 to 9 in a pharmaceutically acceptable form for the treatment or prevention of sickle cell disease and thalassemia, or for the treatment of iron overload syndrome, in particular for the treatment of hereditary hemochromatosis

12. The use of a GlyT1 inhibitor according to any one of claims 5 to 9 for the preparation of a medicament for the treatment or prevention of sickle cell disease and thalassemia, or for the treatment of the iron overload syndrome, in particular for the treatment of hereditary hemochromatosis.